Quarterly report pursuant to Section 13 or 15(d)

LICENSED TECHNOLOGY (Details Textual)

v3.19.1
LICENSED TECHNOLOGY (Details Textual) - USD ($)
1 Months Ended 3 Months Ended
Nov. 04, 2018
Mar. 31, 2019
Mar. 31, 2018
Dec. 31, 2018
Finite-Lived Intangible Asset, Useful Life   20 years    
Payable Due Licensor Non current   $ 20,000,000   $ 20,000,000
Amortization of Intangible Assets   1,345,000 $ 87,000  
Payable Due Licensor Current   $ 10,000,000   $ 10,000,000
Abeona Therapeutics LLC [Member]        
Finite-Lived Intangible Asset, Useful Life   20 years    
REGENXBIO [Member] | Licensing Agreements [Member]        
Payable Due Licensor Non current $ 20,000,000      
Guaranteed Upfront Payment 20,000,000      
Payment on Execution of Contracts 10,000,000      
Annual Fees 100,000,000      
Milestone Payment 60,000,000      
Payable Due Licensor Current $ 10,000,000